has closed the sale of its subsidiary schülke
to EQT, a global investment organization. schülke develops, produces and distributes antiseptics for wound care, disinfectants, medical and cosmetic skin care products and preservatives. The total value of the transaction, which is subject to an earn-out provision, is between €925 million and €1.0 billion ($1.1 billion and $1.17 billion).
This transaction illustrates Air Liquide’s strategy to review its business portfolio regularly and to focus on its core gases and healthcare businesses, thereby enhancing Air Liquide’s performance.
Air Liquide intends to continue to develop its healthcare activities, while providing Schülke & Mayr GmbH with the best opportunity for its long-term development.